One of the major factors driving the market is the rising prevalence of cancer globally. As chemotherapy remains one of the most widely used cancer treatments, the number of patients experiencing neuropathy symptoms such as numbness, tingling, and pain continues to increase. This trend directly contributes to the demand for CIPN treatments. The chemotherapy-induced peripheral neuropathy (CIPN)...